5/31/2012 - Carlos Arteaga, M.D., professor of Medicine and Cancer Biology, associate director of Clinical Research and director of the Breast Cancer Program of the Vanderbilt-Ingram Cancer Center, has been awarded a five-year Clinical Research Professorship grant from the American Cancer Society (ACS).
The $400,000 award is a renewal of a previous grant to Arteaga in 2007 and will support his research focused on the study and development of molecule-targeted therapies in breast cancer.
Only a small number of Clinical Research Professorship grants are renewed by the ACS. This award, which goes into effect July 1, is among 135 national research and training grants awarded by the Society.
“The American Cancer Society has been a wonderful partner in the effort to develop better therapies for patients with breast cancer and I am deeply honored to receive this grant renewal,” said Arteaga. “This award provides generous support of our laboratory-based translational and clinical research on targeted therapies in breast cancer.”
Arteaga joined the Vanderbilt faculty in 1989 and is director of the Vanderbilt-Ingram Specialized Program of Research Excellence (SPORE) in Breast Cancer, which is supported by funding from the National Cancer Institute, a branch of the National Institutes of Health.
He and his group investigate how some molecule-targeted anti-cancer drugs work, why some tumors become resistant to these drugs and how to better select patients who will respond to these novel agents and combinations.
The American Cancer Society is the largest non-government, not-for-profit funding source of cancer research in the United States. Since 1946, the ACS has funded research and training of health professionals to investigate the causes, prevention and early detection of cancer, as well as providing support for cancer patients and their families.